Diabetic Retinopathy Clinical Trial
Official title:
Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage
Verified date | March 2013 |
Source | Bausch & Lomb Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
Status | Completed |
Enrollment | 750 |
Est. completion date | March 2003 |
Est. primary completion date | September 2001 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present >/= 1 month by history or exam - BCVA is worse than 20/200 at time of screening Exclusion Criteria: - Corneal or lenticular abnormalities that preclude fundus observation - Ongoing ocular infection, inflammation or history of herpetic corneal lesion - Current or prior retinal detachment or retinal tears or breaks or intraocular tumor - More than 1 severe vitreous hemorrhage within 6 months - Previous vitrectomy for any reason - Hemorrhage is exclusively pre-retinal, or old & organized - Prior Vitrase for intravitreal injection in either eye - No light perception in either eye at any time - Known contraindications to study medication - Sickle cell disease |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Dalhousie University | Halifax | Nova Scotia |
Canada | Ivey Institute of Ophthalmology | London | Ontario |
Canada | Royal Victoria Hospital | Montreal | Quebec |
Canada | University of Ottawa Eye Institute | Ottawa | Ontario |
Canada | The Medical Centre Pasqua Hospital | Regina | Saskatchewan |
Canada | Centre Hospitalier de l'Universite Laval (CHUL) | Sainte-Foy | Quebec |
Canada | Saskatoon City Hospital | Saskatoon | Saskatchewan |
Canada | Toronto Western Hospital | Toronto | Ontario |
Canada | Vancouver Eye Care Center/University of British Columbia | Vancouver | British Columbia |
Mexico | Instituto de Oftalmologia, Fundacion Conde de Valenciana | Col. Obrera | DF |
Mexico | Association Para Evitar la Ceguera en Mexico | Coyacan | DF |
Mexico | Fundacion Hospital, Nuestra Senora de la Luz IAP | Cuahtemoc | DF |
United States | Retina Center at Pali Momi | Aiea | Hawaii |
United States | Florida Eye Clinic | Altamonte Springs | Florida |
United States | Retina Specialists | Baltimore | Maryland |
United States | Wilmer Eye Institute/Johns Hopkins University School of Medicine | Baltimore | Maryland |
United States | Retina Consultants, PC | Bethesda | Maryland |
United States | Retina Vitreous Associates Medical Group | Beverly Hills | California |
United States | Schepens Retina Associates | Boston | Massachusetts |
United States | Charlotte Eye, Ear, Nose & Throat Association | Charlotte | North Carolina |
United States | Illinois Retina Associates SC | Chicago | Illinois |
United States | University of Chicago | Chicago | Illinois |
United States | Maria E. Castillejos, MD | Chula Vista | California |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Retina Associates of Cleveland | Cleveland | Ohio |
United States | Retina Consultants of Southern Colorado | Colorado Springs | Colorado |
United States | Retina Consultants, Ohio State University | Columbus | Ohio |
United States | Danbury Eye Physicians & Surgeons | Danbury | Connecticut |
United States | University of Colorado Health Sciences Center | Denver | Colorado |
United States | Eye Centers of Florida | Fort Myers | Florida |
United States | Eye Medical Center of Fresno | Fresno | California |
United States | Natural Vision | Fresno | California |
United States | VitreoRetinal Associates | Grand Rapids | Michigan |
United States | Long Island Vitreo Retinal Consultants | Great Neck | New York |
United States | New England Retina Associates | Hamden | Connecticut |
United States | Cullen Eye Institute/Baylor College of Medicine | Houston | Texas |
United States | Retinal Vascular Center | Houston | Texas |
United States | Jerry Sebag, MD | Huntington Beach | California |
United States | University of California, Irvine | Irvine | California |
United States | Hunkeler Eye Centers | Kansas City | Missouri |
United States | Retina Associates of Kansas City | Kansas City | Missouri |
United States | Southeastern Retina Associates, PC | Knoxville | Tennessee |
United States | Valley Retina Institute, PA | McAllen | Texas |
United States | California VitreRetinal Center | Menlo Park | California |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Retina Center PA | Minneapolis | Minnesota |
United States | Retina-Vitreous Associates | Nashville | Tennessee |
United States | American Eye Institute | New Albany | Indiana |
United States | Robert Wood Johnson Medical School/Retina Vitreous Center | New Brunswick | New Jersey |
United States | Kurt A. Gitter, MD | New Orleans | Louisiana |
United States | Ronni M. Lieberman, MD | New York | New York |
United States | Dean A. McGee Eye Institute | Oklahoma City | Oklahoma |
United States | Southern California Desert Retina Consultants | Palm Springs | California |
United States | Retina Research of Wills Eye Hospital | Philadelphia | Pennsylvania |
United States | Scheie Eye Institute | Philadelphia | Pennsylvania |
United States | Felix N. Sabates Eye Associates | Prairie Village | Kansas |
United States | Carolina Eye Associates, PA | Raleigh | North Carolina |
United States | Vista Retinal Consultants | Roanoke | Virginia |
United States | Retinal Consultants | Sacramento | California |
United States | John Moran Eye Center | Salt Lake City | Utah |
United States | H. Richard McDonald, MD | San Francisco | California |
United States | Santa Clara Valley Medical Centre | San Jose | California |
United States | Robert L. Avery, MD | Santa Barbara | California |
United States | Sarasota Retina Institute | Sarasota | Florida |
United States | Virginia Mason Medical Center | Seattle | Washington |
United States | King Y. Lee, MD | Shawnee Mission | Kansas |
United States | The Center for Advanced Medicine/Barnes Retina Institute | St. Louis | Missouri |
United States | Olive View/UCLA Medical Center | Sylmar | California |
United States | Retina Vitreous Surgeons of Central NY | Syracuse | New York |
United States | Scott E. Pautler, MD | Tampa | Florida |
United States | Retina Associates of New Jersey | Teaneck | New Jersey |
United States | Retina Centers, PC | Tucson | Arizona |
United States | Carim Eye & Retina Center | Wyomissing | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Bausch & Lomb Incorporated |
United States, Canada, Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Resolution of Vitreous Hemorrhage | Laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula & at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved | 3 months | No |
Secondary | Incidence of complications & adverse events | 12 months | No | |
Secondary | Visual Acuity | Best correct visual acuity (BCVA) | 3 months, 6 months, 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
Completed |
NCT03660384 -
Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy
|
N/A | |
Completed |
NCT04905459 -
ARDA Software for the Detection of mtmDR
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT05022615 -
Comparing 3 Imaging Systems
|
||
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT03702374 -
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
|
Phase 3 | |
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT04009980 -
Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.
|
N/A | |
Completed |
NCT02924311 -
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
|
||
Not yet recruiting |
NCT06257082 -
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
|
N/A | |
Not yet recruiting |
NCT05452993 -
Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography
|
N/A | |
Withdrawn |
NCT02812030 -
Aflibercept for Retinopathy in the Real World
|
N/A | |
Completed |
NCT02391558 -
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography
|
N/A | |
Active, not recruiting |
NCT02353923 -
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
|
N/A | |
Active, not recruiting |
NCT02330042 -
OCT Biomarkers for Diabetic Retinopathy
|
||
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |